REC-4881 cuts total polyp burden by median 47% at 12 weeks in Phase 2 FAP trial, data show deep durable reductions

Recursion says REC-4881 reduced total polyp burden by a median 47% after 12 weeks in a 15-patient single-arm Phase 2 trial in familial adenomatous polyposis, with data presented at CGA-IGC showing deep, durable reductions, activity across the GI tract and in larger, higher-risk polyps.

Detected & updated continuously · Source: Nebula